Table 5.
Variation in anthropometric measures, MEDI-LITE score, and lipid profile after the nutritional counseling.
| VARIABLES | Baseline [Mean ± SD; Median; IQR] |
Follow-up [Mean ± SD; Median; IQR] |
Absolute Variation [Mean ± SD; Median; IQR] |
Percentage Variation [%] |
p-Value † |
|---|---|---|---|---|---|
| Weight [kg: mean ± SD; median; IQR] | 75.7 ± 17.5; 74.3 (62.5, 84.0) |
72.8 ± 15.8; 71.0 (60.0, 83.5) |
−2.5 ± 3.5; −2.0 (−3.3, 0) |
−3.2% | <0.0001 |
| BMI [kg/m2: mean ± SD; median; IQR] | 26.3 ± 4.7; 26.0 (22.9, 28.8) |
25.2 ± 4.0; 25.5 (22.1, 27.4) |
−9 ± 1.2; −0.6 (−1.2, 0) |
−3.3% | <0.0001 |
| MEDI-LITE [Points: mean ± SD; median; IQ range] | 10 ± 3; 10 (8, 12) |
13 ± 2; 14 (12, 15) |
3 ± 3; 3 (1, 5) |
+43.4% | <0.0001 |
| TC [mg/dl: mean ± SD; median, IQR] |
|||||
| Diet alone | 249 ± 36; 255 (222, 267) |
207 ± 54; 204 (158, 248) |
−42 ± 54; −23 (−87, −1) |
−16.2% | 0.002 |
| Lipid-lowering Nutraceuticals | 257 ± 39; 261 (232, 270) |
211 ± 39; 204 (190, 213) |
−38 ± 34; −42 (−67, 0) |
−15.1% | 0.046 |
| Lipid-lowering Drugs | 238 ± 67; 234 (179, 294) |
170 ± 30; 173 (140, 196) |
−83 ± 61; −73 (−119, −33) |
−29.3% | <0.0001 |
| HDL-C [mg/dl: mean ± SD; median, IQR] | |||||
| Diet alone | 58 ± 21; 53 (42, 67) |
60 ± 20; 54 (47, 68) |
0 ± 7; 0 (−3, 4) |
2.5% | 0.641 |
| Lipid-lowering Nutraceuticals | 58 ± 26; 46 (40, 63) |
55 ± 17; 50 (40, 72) |
0 ± 9; 0 (−2, 7) |
3.4% | 0.753 |
| Lipid-lowering Drugs | 54 ± 15; 52 (42, 66) |
50 ± 12; 48 (40, 61) |
−2 ± 8; −3 (−5, 4) |
−2.5% | 0.383 |
| LDL-C [mg/dl: mean ± SD; median, IQR] | |||||
| Diet alone | 161 ± 35; 150 (138, 187) |
123 ± 47; 129 (83, 170) |
−32 ± 49; −22 (−78, 0) |
−18.6% | 0.026 |
| Lipid-lowering Nutraceuticals | 180 ± 33; 179 (154, 196) |
132 ± 34; 131 (102, 145) |
−39 ± 37; −39 (−52, −9) |
−22.6% | 0.068 |
| Lipid-lowering Drugs | 146 ± 60; 147 (95, 185) |
90 ± 29; 100 (70, 112) |
−71 ± 50; −66 (−111, −22) |
−38.3% | 0.001 |
| TG [mg/dl: mean ± SD; median, IQR] |
|||||
| Diet alone | 184 ± 123; 130 (103, 254) |
129 ± 66; 111 (85, 167) |
−39 ± 83; −17 (−44, 0) |
−15.2% | 0.025 |
| Lipid-lowering Nutraceuticals | 192 ± 149; 119 (102, 208) |
125 ± 56; 102 (90, 177) |
−54 ± 104; −10 (−81, 0) |
−16.8% | 0.173 |
| Lipid-lowering Drugs | 218 ± 228; 138 (104, 206) |
152 ± 105; 123 (90, 158) |
−80 ± 200; −45 (−63, 0) |
−16.7% | 0.013 |
Abbreviations: BMI = body mass index, IQR= Interquartile range. † p-values for dependent samples nonparametric Wilcoxon Signed Ranks Test between baseline and follow-up values.